Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

John F. Alderete

John F. Alderete

Washington State University,USA

Title: A Recombinant Chimeric Protein Comprised of Immunogenic Epitopes of Metabolic Enzymes is Serodiagnostic Target for Trichomonas vaginalis Sexually Transmitted Infections

Biography

Biography: John F. Alderete

Abstract

There is a need for a rapid, inexpensive and accurate serum antibody-based diagnostic with targets of high specificity for screening of large cohorts of women and men at risk of infection by Trichomonas vaginalis. This protist causes the number one non-viral sexually transmitted infection worldwide. The antigen-detection OSOM™ Trichomonas Rapid Test (Seskui Diagnostics) is a lateral flow, immunochromatographic Point-of-Care test that works only for women. During the course of our investigations of the T. vaginalis-host interactions, highly immunogenic proteins detected by sera of patients with trichomonosis but not uninfected controls were identified. Some of these immunogenic proteins include the metabolic enzymes fructose-1,6-bisphosphate aldolase (A), α-enolase (E), and glyceraldehyde-3-phosphate dehydrogenase (G). The epitopes of these proteins were characterized and found to have little or no sequence identity to other eukaryotes, yeasts, and microbial pathogens, including organisms that cause other STIs. We have constructed a new version of an earlier chimeric recombinant String-Of-Epitopes (SOE) protein consisting of 15-mer peptides of epitopes of A, E, and G (ImmunoTargets Therapy, 2013:2, 91-103). This composite protein called AEG::SOE2 was detected by ELISA with highly reactive sera of women and men but not control, negative serum lacking antibody to T. vaginalis. I believe that this approach lends itself to the creation of highly specific immunogenic targets for both detection of serum antibody in patients as well as for future subunit vaccines